Haemoglobin A1c and serum glucose levels and risk of gastric cancer: a systematic review and meta-analysis

Jiaojiao Zheng1,2, Yunhe Gao3, Shao-Hua Xie1,4✉, Giola Santoni1 and Jesper Lagergren1,5

© The Author(s) 2022, corrected publication 2021

Epidemiology

Haemoglobin A1c and serum glucose levels and risk of gastric cancer: a systematic review and meta-analysis

Jiaojiao Zheng1,2, Yunhe Gao3, Shao-Hua Xie1,4✉, Giola Santoni1 and Jesper Lagergren1,5

© The Author(s) 2022, corrected publication 2021

BACKGROUND: This systematic review and meta-analysis examined associations between serum levels of haemoglobin A1c (HbA1c) and glucose and the risk of gastric cancer.

METHODS: MEDLINE, Embase, and Cochrane Library were searched for studies examining associations between serum levels of HbA1c or glucose and the risk of gastric cancer. Inclusion of studies, quality assessment, and data extraction were conducted independently by two authors. Pooled hazard ratios (HR) with 95% confidence intervals (CI) were synthesised using random-effects models. Cochran’s Q test and I² statistic were used to assess heterogeneity.

RESULTS: Among 3473 identified studies, 12 were included. Of these, 5 studies examined HbA1c levels and 7 studies examined serum glucose levels. Serum HbA1c levels >6% were associated with an increased risk of gastric cancer (HR 1.36, 95% CI 1.06–1.74). When compared with the lowest glucose categories, the highest glucose categories were associated with a borderline increased risk of gastric cancer (HR 1.11, 95% CI 0.98–1.26). In subgroup analyses, studies that adjusted for Helicobacter pylori infection indicated stronger associations between elevated HbA1c levels and gastric cancer (HR 2.08, 95% CI 1.46–2.98) than those without such adjustment (HR 1.10, 95% CI 0.91–1.32).

CONCLUSIONS: Long-standing poor glycaemic control may increase the risk of gastric cancer.

REGISTRATION NUMBER: PROSPERO CRD42020157453.

British Journal of Cancer (2022) 126:1100–1107; https://doi.org/10.1038/s41416-021-01693-3

INTRODUCTION

Gastric cancer occurs in over one million individuals and causes nearly 800,000 deaths each year globally [1]. The incidence of gastric cancer is higher in East Asian countries than in Western countries [1]. The overall prognosis in gastric cancer is poor with a 5-year survival rate below 30% in most countries [2].

Diabetes mellitus is a chronic metabolic disease with increasing prevalence and is characterised by elevated serum levels of glucose and glycate haemoglobin A1c (HbA1c). Diabetes increases the risk of some tumours, but studies that have investigated diabetes in relation to the risk of developing gastric cancer have yielded conflicting results [3–6]. The inconsistency across these studies might, at least partly, be due to different methods of defining diabetes, ranging from diagnosis codes to use of anti-diabetes medications [4, 5, 7]. These differences may have introduced heterogeneity in the meta-analyses that pooled results from these studies [8–10]. In contrast, this systematic review and meta-analysis specifically investigated whether elevated levels of measured glucose biomarkers in serum, i.e. HbA1c and glucose, are associated with an increased risk of gastric cancer. These two biomarkers were chosen as they were the most common measurements for diabetes in clinical practice [11].

METHODS

Search strategy and study selection

This systematic review and meta-analysis was performed and reported in accordance with the MOOSE guidelines [12]. The study protocol was registered on PROSPERO (CRD42020157453) before the systematic search was conducted. The literature search strategy (presented in detail in Supplementary Part 1) was discussed and agreed upon by all authors and was consulted with librarians at Karolinska Institutet. The systematic search for studies reporting associations between serum levels of HbA1c or glucose and the risk of gastric cancer was conducted in three databases: MEDLINE, Embase, and Cochrane Library. The original search was conducted on 15th December 2019, and was updated on 6th January 2021. No search restrictions were applied. In addition to the electronic search, reference lists of all included studies and relevant review articles were searched manually [8–10, 13–21]. Corresponding authors of three conference abstracts were contacted and one provided the full study [22]. Studies fulfilling the following criteria underwent full-text review: (a) original data on the associations between serum levels of HbA1c or...
glucose and the risk of gastric cancer; (b) cohort studies, case–control studies or randomised clinical trials where serum HbA1c or glucose levels were measured before the onset of gastric cancer; and (c) full-text reports available in English language. Studies reporting mortality from gastric cancer as a surrogate of incidence were excluded. Whenever multiple reports were based on the same study population, only the one with the largest sample size was included. However, if two studies from the same study population reported HbA1c and serum glucose separately, both studies were included. One author (UZ) retrieved the results from the databases and removed duplicates. The initial screening of study titles and abstracts, two rounds of full-text reviews, and the final inclusion of studies were performed independently by two authors (UZ and YG). Any disagreement was solved by consultation with a third author (SX).

Quality assessment and data extraction

The quality of the included studies was independently assessed by two authors (UZ and YG) using a modified Newcastle-Ottawa Scale for cohort studies [23], where three sources of bias (selection bias, information bias, and confounding) were evaluated. The evaluation of each type of bias included 3–6 items and was summarised into low, moderate, or high risk of bias. The quality of the only included nested case–control study [4] was evaluated with reference to its source cohort [24]. A study assessed as no high risk in any of the three sources of bias and low risk in at least two sources of bias was defined as low risk of bias in general, whereas studies that did not meet these criteria were defined as having moderate to high risk of bias [25].

One author (UZ) recorded descriptive details for each included study, i.e. authorship, publication year, study design, setting, country, age and sex distribution of participants, total number of participants, study period, follow-up time, exposure (HbA1c or glucose), primary outcome, and number of incident gastric cancer cases. Relative risk estimates of the association, i.e. hazard ratios (HR), risk ratios or odds ratios and their 95% confidence intervals (CI) were independently extracted by two authors (UZ and YG). When multiple estimates were provided in the same study, we selected the estimates adjusted for four predefined potential confounders, i.e. sex, age, obesity and Helicobacter pylori infection. If the reported risk estimates were not adjusted for all these variables, the one adjusted for most of these confounders was used. If the results were reported separately for men and women in a study, both estimates were retrieved and treated as two separate results in the later analyses.

Any disagreement during the quality assessment or data extraction was solved together with a third author (SX).

Statistical analysis

Associations between serum levels of HbA1c or glucose and the risk of gastric cancer were pooled using a random-effects model. Because all but one included study estimated HRs, and the remaining one estimated odds ratios, which were assumed to approximate HRs under the rare disease condition, HRs were used to synthesise the associations.

Studies reporting HbA1c had generally similar categorisations of HbA1c levels. The HRs were pooled comparing the HbA1c levels >6% with <6%, and also for the categories 6%–7% and >7%, both with the reference level <6%. Studies reporting serum glucose levels had different cut-offs. Therefore, we pooled the HRs comparing the highest category with the lowest category. Five studies of serum glucose levels used quartile or quintile cut-off values, [4, 22, 26–28] and the retrieved HRs were converted into estimates comparing the highest with the lowest tertiles to minimise heterogeneity across studies according to the method reported by Genevieve et al. [29]. Where appropriate, HRs from studies reporting fasting glucose were also pooled into the categories 6–7 mmol/L and >7 mmol/L, both with the reference level <6 mmol/L. The pooling of HRs was performed according to the method reported by Tierney et al. [30], using the generic inverse-variance method proposed by the Cochrane Handbook [31].

Heterogeneity across studies was assessed by Cochran’s Q test and χ² statistics. A P value <0.1 in the Cochran’s Q test was considered statistically significant [31]. An χ² value ≤25% represented low heterogeneity, 25–49% moderate heterogeneity, and ≥50% high heterogeneity [32]. To explore potential sources of heterogeneity, subgroup analyses were conducted by sex (female or male), geographic area (Asian or non-Asian countries), risk of bias (moderate to high or low), adjustment for obesity (yes or no), and adjustment for Helicobacter pylori infection (yes or no). In a sensitivity analysis of serum glucose, the only case–control study was excluded [4].

Because none of the included studies specified whether it was type I or type II diabetes in participants with hyperglycaemia, type I and type II diabetes were not analysed separately.

Publication bias was evaluated by the visual inspection of funnel plots, Egger’s test, and a nonparametric trim-and-fill analysis. All analyses were conducted using Stata 16 (StataCorp, College Station, Texas, USA). All statistical tests were two-sided.

RESULTS

Literature search and study characteristics

The search and selection of studies are presented in a flowchart (Fig. 1). Among 3473 publications identified from the electronic databases and reference list search, 12 studies met the inclusion criteria. Of these studies, 5 reported serum HbA1c levels [33–37], and 7 investigated serum glucose levels. [4, 22, 26–28, 38, 39] Among the studies reporting serum glucose levels, 4 analysed fasting samples [22, 26, 28, 38], 2 analysed random samples [4, 39], and the remaining study analysed both [27]. Among all included studies, 11 were cohort studies [22, 26–28, 33–39] and one was a nested case–control study [4]. Eight studies were conducted in Asia, [4, 26, 28, 34–36, 38, 39] 3 in Europe [22, 27, 37], and 1 in New Zealand [33]. Nine studies were based on screening programmes, surveys, or routine health check-ups. The study period of the included studies ranged from 1972 to 2016. Two studies were based on the same study population, but reported serum levels of HbA1c and glucose in relation to risk of gastric cancer in separate publications [26, 34]. All studies included both sexes, and 3 reported sex-specific risk estimates [4, 27, 38]. Six studies analysed diabetes biomarkers in relation to the risk of multiple cancer types, including gastric cancer, [22, 33, 35, 37–39] while the other 6 investigated gastric cancer risk only, [4, 26–28, 34, 36] including 2 that specifically studied gastric adenocarcinoma (Table 1) [27, 28].

Quality assessment

The overall quality of included studies in terms of risk of bias is summarised in Table 1, and a more detailed assessment is provided in the Supplementary Table 1. Five studies had low overall risk of bias and the other 7 had moderate to high risk of bias. More specially, 6 studies had moderate to high risk of selection bias, 6 studies had moderate to high risk of information bias, and 8 studies had moderate to high risk of bias due to confounding. All 12 studies adjusted for sex and age in their main analyses, 8 adjusted for obesity, and 4 adjusted for Helicobacter pylori infection. In addition, 11 studies adjusted for tobacco smoking (Supplementary Table 2).

HbA1c levels and risk of gastric cancer

The meta-analysis of HbA1c included 562,590 participants from 5 studies, of whom 821 (0.1%) developed gastric cancer during follow-up. Random-effects meta-analysis showed that HbA1c >6% were associated with an increased risk of gastric cancer (pooled HR 1.36, 95% CI 1.06-1.74) (Fig. 2). When pooling HRs by the three cut-offs of HbA1c, the pooled HRs were 1.36 (95% CI 0.91–2.02) for the cut-off 6–7% vs <6%, and 1.39 (95% CI 1.00–1.94) for the cut-off >7% vs <6% (as shown in Supplementary Fig. 1). There was moderate heterogeneity across these studies (I² = 43%, P in Q test = 0.43). Subgroup analysis showed that adjustment for Helicobacter pylori infection was a source of heterogeneity among studies (P for group difference = 0.002), and the association between elevated HbA1c levels and risk of gastric cancer was stronger in studies with adjustment for Helicobacter pylori infection (pooled HR 2.08, 95% CI 1.46–2.98) than those without such adjustment (pooled HR 1.10, 95% CI 0.91–1.32) (Table 2). Subgroup analyses by sex, geographic area, risk of bias, or adjustment for obesity did not reveal any of these factors as sources of heterogeneity (Table 2).
Serum glucose levels and risk of gastric cancer

The meta-analysis of serum glucose included 3,075,546 participants from 10 studies. Of these, 4787 (0.2%) participants developed gastric cancer, but the number of participants developing gastric cancer was missing in one study [38]. Random-effects meta-analysis showed a borderline increased risk of gastric cancer associated with the highest categories of serum glucose compared with lowest categories (pooled HR 1.11, 95% CI 0.98–1.26) (Fig. 3). There was high heterogeneity ($I^2 = 70\%$, $P$ in Q test = 0.001) across studies. The pooled HRs between levels of fasting glucose and risk of gastric cancer were 1.16 (95% CI 0.86–1.55) for the cut-off 6–7 mmol/L vs < 6 mmol/L, and 1.00 (95% CI 0.89–1.13) for the cut-off >7 mmol/L vs < 6 mmol/L (as shown in Supplementary Fig. 2). Subgroup analyses by sex, geographic area, risk of bias, adjustment for obesity, or adjustment for Helicobacter pylori infection did not reveal any of these factors as sources of heterogeneity (Table 2). The sensitivity analysis excluding the nested case–control study yielded a similar risk estimate as that of the main analysis (pooled HR 1.13, 95% CI 0.99–1.28).

Publication bias

Asymmetry was suggested for studies reporting serum HbA1c and glucose in the funnel plots (Fig. 4). The Egger’s tests showed no evidence of publication bias for studies reporting HbA1c ($P = 0.292$), but for studies reporting serum glucose ($P = 0.055$). When imputing potential missing studies with trim-and-fill analysis, the pooled HR for serum glucose became slightly attenuated (pooled HR 1.05, 95% CI 0.89–1.24).

DISCUSSION

This is the first systematic review and meta-analysis examining measured serum levels of HbA1c and glucose in relation to the risk of developing gastric cancer. The results indicate that long-standing poor glycaemic control, as indicated by elevated HbA1c levels, increases the risk of gastric cancer, while the association between elevated serum glucose levels and gastric cancer is less clear.

Strengths of this study include an a priori defined protocol, broad and systematic search strategy, and assessment of different sources of bias. There are also limitations. First, the number of studies was limited and some important information, e.g. history of medication use and the diagnosis of diabetes, were not reported in most individual studies, reducing the possibility and statistical power for more subgroup analyses. Second, the cut-off values of serum HbA1c and glucose were not completely in
| Biomarker          | First author and publication year | Study design     | Settings       | Country            | Number of participants | Male (%) | Age distribution (years) | Study period (mean/median follow-up in years) | Primary outcome | Number of gastric cancer cases | Overall risk of bias |
|--------------------|-----------------------------------|-----------------|----------------|--------------------|------------------------|----------|--------------------------|----------------------------------------------|-----------------|-----------------------------|------------------|
| HbA1c              | Travier 2007                      | Cohort          | Screening      | New Zealand        | 46,575                 | 44.6     | >= 18, and more than 60% <40 | 1999–2004 (4.4)                                  | All cancer incidence | 25                          | Moderate to high    |
| HbA1c              | Ikeda 2009                        | Cohort          | Screening      | Japan              | 2603                   | 41.2     | Mean age 59.2             | 1988–2002 (not reported)                         | Gastric cancer incidence | 97                          | Low              |
| HbA1c              | Goto 2016                         | Cohort          | Health check-up | Japan              | 29,629                 | 38.3     | Mean age 62.6             | 1998–2008 (8.5)                                  | All cancer incidence | 282                         | Low               |
| HbA1c              | Cheung 2019                       | Cohort          | Registry-based cohort | China (Hong Kong)   | 7266                   | 52.0     | Median age 65.2 (interquartile range 56.1–74.2) | 2003–2015 (5.5)                                  | Gastric cancer incidence | 37                          | Low               |
| HbA1c              | Peila 2020                        | Cohort          | Biobank cohort | United Kingdom     | 476,517                | 45.6     | Mean age 56.4             | 2006–2016 (7.1)                                  | All cancer incidence | 380                         | Moderate to high   |
| Serum glucose      | Jee 2005                          | Cohort          | Health check-up | Korea              | 1,298,385              | 63.9     | Mean age for men 45.3; mean age for women 49.6 | 1992–2002 (not reported)                         | All cancer incidence | Not reported              | Moderate to high   |
| Serum glucose      | Yamagata 2005                     | Cohort          | Screening      | Japan              | 2,466                  | 41.7     | Mean age for men 57.5; mean age for women 58.8 | 1988–1997 (not reported)                        | Gastric cancer incidence | 66                          | Low               |
| Serum glucose      | Wulaningsih 2012                  | Cohort          | Screening      | Sweden             | 540,309                | 53.7     | Mean age for participants with gastric cancer 57.8 | 1985–2002 (12)                                   | Incidence of cancer of the oesophagus, stomach, colon, and rectum | 776                         | Moderate to high   |
| Serum glucose      | Lindkvist 2013                    | Cohort          | Registry-based cohorts | Norway, Austria, Sweden | 578,700                | 50.1     | Mean age for men 43.9; mean age for women 44.1 | Norwegian cohorts 1972–2003; Austrian cohort 1985–2003; Swedish cohorts 1985–2006 (10.4) | Gastric adenocarcinoma incidence | 1210                        | Moderate to high   |
| Serum glucose      | Hidaka 2015                       | Nested case-control | Screening      | Japan              | 123,576                | 66.9     | Mean age 57.2             | 1990–2004 (not applicable)                       | Gastric cancer incidence | 477                         | Low               |
| Serum glucose      | Kim 2016                          | Cohort          | Health check-up | Korea              | 23,218                 | 62.4     | Mean age for participants with gastric cancer 56.5; mean age for participants without gastric cancer 53.2 | 2004–2015 (6.8)                                  | Gastric adenocarcinoma incidence | 154                        | Moderate to high   |
| Serum glucose      | Pan 2018                          | Cohort          | Prospective cohorts | China             | 508,892                | 41.0     | Age range 30–79; more than 75% between 30–59 | 2004–2013 (7.1)                                 | All cancer incidence | 2104                        | Moderate to high   |

*Assessed by the Newcastle-Ottawa Scale, for which the details are available in Supplementary Table 1.

*Haemoglobin A1c.*
accordance with the clinical definitions of diabetes and pre-diabetes. Third, there was high heterogeneity across studies evaluating serum glucose that were not explained by differences in population characteristics or potential biases [40]. Forth, publication bias for studies investigating serum glucose levels could not be ruled out.

Possible mechanisms for hyperglycaemia leading to gastric cancer include promotion of cancer cell proliferation [41], induction of gastric mucosa atrophy [42], and influence on the insulin/insulin-like growth factors axis, which regulates proliferation, invasion, and apoptosis of gastric cancer cells [43, 44]. A potential explanation for the association between HbA1c levels, rather than glucose levels, and risk of gastric cancer might be that the carcinogenic influence of hyperglycaemia depends on the duration of it. While a single serum glucose test represents only a transitory status of blood glucose which is subject to many factors, e.g. fasting time and anti-diabetes medication, HbA1c levels reflect the average glucose levels during the past 2–3 months, and time-average HbA1c levels, which take into account of serial HbA1c measurements, reflect glycaemic status for even longer periods. A previous study suggested an association between diabetes and risk of gastric cancer only at least 5 years after the diabetes diagnosis [7]. Another study found that only long-lastingly elevated serum glucose levels (but not other trajectory patterns) were associated with an increased risk of gastrointestinal cancer (HR 1.66, 95% CI 1.22–2.26) [45]. Another potential link between high HbA1c levels and gastric carcinogenesis might be the treatment for long-term poor glycaemic control. Among many

| First author and year | Haemoglobin A1c | Serum glucose |
|-----------------------|-----------------|---------------|
|                       | Number of studies | Pooled HR (95% CI) | P\text{Heterogeneity}\textsuperscript{a} | P\text{Difference}\textsuperscript{b} | I\textsuperscript{2} (%) | Number of studies | Pooled HR (95% CI) | P\text{Heterogeneity}\textsuperscript{a} | P\text{Difference}\textsuperscript{b} | I\textsuperscript{2} (%)|
| Geographical area     |                 |                 |             |             |                     |                 |                 |             |             |                     |
| Asia                  | 3               | 1.51 (1.03–2.21) | 0.07        | 0.13        | 54                  | 5               | 1.14 (0.96–1.35) | 0.13        | 0.73        | 75                  |
| Non-Asia              | 2               | 1.14 (0.89–1.45) | 0.36        |             | 7                   | 2               | 1.08 (0.86–1.36) | 0.49        |             | 71                  |
| Sex                   |                 |                 |             |             |                     |                 |                 |             |             |                     |
| Male                  | 2               | 1.08 (0.86–1.36) | 0.55        | 0.92        | 0                   | 3               | 0.99 (0.92–1.08) | 0.94        | 0.64        | 0                   |
| Female                | 2               | 1.10 (0.71–1.69) | 0.24        |             | 29.5               | 3               | 1.08 (0.75–1.56) | 0.02        |             | 74                  |
| Assessment of risk of bias |             |                 |             |             |                     |                 |                 |             |             |                     |
| Moderate              | 2               | 1.14 (0.89–1.45) | 0.36        | 0.13        | 7                   | 5               | 1.09 (0.98–1.22) | 0.01        | 0.58        | 88                  |
| High                  | 3               | 1.51 (1.03–2.21) | 0.07        |             | 54                  | 2               | 1.57 (0.44–5.63) | <0.01       |             | 66                  |
| Adjustment for Helicobacter pylori infection | | | | | | | | | | |
| Yes                   | 2               | 2.08 (1.46–2.98) | 0.63        | <0.01       | 0                   | 2               | 1.57 (0.44–5.63) | <0.01       | 0.58        | 66                  |
| No                    | 3               | 1.10 (0.91–1.32) | 0.62        |             | 0                   | 5               | 1.09 (0.98–1.22) | 0.01        |             | 88                  |
| Adjustment for obesity |                 |                 |             |             |                     |                 |                 |             |             |                     |
| Yes                   | 3               | 1.32 (0.99–1.76) | 0.03        | 0.30        | 58.4                | 5               | 1.16 (0.96–1.42) | <0.01       | 0.23        | 75                  |
| No                    | 2               | 1.68 (0.95–2.95) | 0.61        |             | 0                   | 2               | 1.02 (0.93–1.11) | 0.32        |             | 12                  |

HR: hazard ratio, CI: confidence interval.
\textsuperscript{a}P value in Cochran’s Q test.
\textsuperscript{b}P value in the test of subgroup difference.
anti-diabetes medications, metformin (the first-line oral medication for diabetes) may decrease the risk of gastric cancer, while insulin might increase this risk [46, 47]. Although no previous systematic reviews and meta-analyses have examined diabetes biomarkers and the specific risk of developing gastric cancer, one study has suggested an increasing log-linear trend between HbA1c levels and gastric cancer [21]. Another meta-analysis of prediabetic levels of serum glucose suggested an increased risk of mortality from combined gastric and colorectal cancers (pooled relative risk 1.55, 95% CI 1.15–2.09) [16]. However, that study assessed cancer mortality rather than incidence and did not separately analyse gastric cancer.

Nevertheless, several systematic reviews and meta-analyses have evaluated diabetes (assessed by different methods) in relation to gastric cancer risk [8–10, 14, 17]. Two systematic review and meta-analyses found a positive association [9, 17], two suggested a positive association of borderline statistical significance [10, 14], and the most recent one found no association [8]. None of these meta-analyses accounted for the different methods of assessing diabetes in individual studies, which ranged widely from self-reported diabetes, diagnosis codes identified from medical records, data from healthcare registries or health insurances, use of anti-diabetic medication, to objectively measured diabetes biomarkers [4, 5, 7, 34, 48]. These differences may explain the high heterogeneity (I² ranging from 70 to 95%) in the previous meta-analyses. The strict inclusion of only studies that examined objectively measured serum HbA1c in the present study counteracted the heterogeneity in the analysis of HbA1c. The remaining high heterogeneity in the analysis of serum glucose may be due to different cut-offs for glucose levels in individual studies as well as the mix of fasting and non-fasting serum glucose levels. This explains the decreased heterogeneity when pooling the data for fasting serum glucose only.

Some meta-analyses that examined diabetes and risk of gastric cancer indicated stronger associations among women [9, 10, 17] and East Asians [9, 14], which, however, was inconsistent with other meta-analyses [8, 10, 14, 17]. In the present study, subgroup analyses found no clear differences by sex, but a seemingly stronger association between HbA1c and risk of gastric cancer in the Asian populations than in the non-Asian populations was indicated, although the difference between the two groups was not statistically significant. The present study also showed a stronger association between elevated HbA1c and gastric cancer in studies adjusting for Helicobacter pylori infection. Helicobacter pylori infection is the strongest risk factor for gastric cancer. Experimental studies have suggested that Helicobacter pylori infection might lead to hyperglycaemia, and thus confound the association between hyperglycaemia and risk of gastric cancer [49]. On the other hand, hyperglycaemia might stimulate Helicobacter pylori infection via various mechanisms, including enhancing its proliferation, viability, adhesion and CagA-phosphorylation [50]. Therefore, Helicobacter pylori infection might also act as a mediator in the development of gastric cancer associated with hyperglycaemia. Stratified analyses by Helicobacter pylori infection status and mediation analysis are warranted to clarify the interaction of hyperglycaemia and Helicobacter pylori infection in gastric cancer in the future.

The increased risk of gastric cancer among participants with high levels of HbA1c found in the present study indicates that individuals with poor glycaemic control for long periods may be a
risk group for gastric cancer. However, given the limited number of studies published, more evidence is needed to confirm this association. More importantly, as most included studies in this review analysed multiple cancer sites, studies specifically analysing gastric cancer are needed to conduct meaningful subgroup analyses by sub-localisations and known risk factors of gastric cancer. Last, any interactions between elevated levels of HbA1c and other factors, e.g. sex, ethnicity, diabetes treatment, and use of other medications such as statins or aspirin, in the development of gastric cancer are not clear and evidence from more large prospective studies is needed.

To conclude, this systematic review and meta-analysis indicates that long-term hyperglycaemia, as measured by HbA1c, increases the risk of gastric cancer.

DATA AVAILABILITY
The full texts of all included studies were retrieved from the online databases Embase and MEDLINE. The data of this systematic review and meta-analyses are all public and available from Embase and Medline.

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,687 patients from 27 population-based registries in 67 countries (CONCORD-2). Lancet (Lond, Engl). 2015;385:977–1010.

10. Ge Z, Ben Q, Qian J, Wang Y, Li Y. Diabetes mellitus and risk of gastric cancer: a meta-analysis. World J Gastroenterol. 2013;19:6902.
11. Hai H, Hara D, Hara M, Hara M, Hara M, Hara M, et al. The potential role of inflammatory factors, e.g. sex, ethnicity, diabetes treatment, and use of other medications such as statins or aspirin, in the development of gastric cancer are not clear and evidence from more large prospective studies is needed.
12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.
13. Crawford CJ, Hofseth LJ, Melvin JC, Loda M, Chowdhury S, Rudman SM, et al. Serum glucose and risk of cancer: a meta-analysis. BMC Cancer. 2014;14:1466.
14. Tian T, Zhang LQ, Ma XH, Zhou JN, Shen J. Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis. Exp Clin Endocrinol Diabetes. 2012;120:217–23.
15. Johnson JA, Bowker SL. Intensive glycemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011;54:25–31.
16. Huang Y, Cai X, Qiu M, Chen P, Tang H, Hu Y, et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014;57:2261–9.
17. Youn JM, Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis. World J Gastroenterol. 2013;19:936–45.
18. Noto H, Tsuchimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: a meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Investig. 2012;3:24–33.
19. Tseng CH, Tseng FH. Diabetes and gastric cancer: the potential links. World J Gastroenterol. 2014;20:1701–11.
20. Li Z, Han H, Chang Y. Association between metabolic syndrome and the incidence of gastric cancer: a meta-analysis of cohort studies. Diabetol Metab Syndr. 2011;9:183.
21. De Beer JC, Liebenberg L. Does cancer risk increase with HbaA1c, independent of diabetes? Br J Cancer. 2014;110:2361–8.
22. Wuilingshw G, Garmo H, Holmgren L, Hammar N, Jungner I, Walldius G, et al. Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. J Cancer Epidemiol 2012;2012:792034.
23. Wells GA, Shea B, O’Connor D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2020; http://www.ohr.washington.edu/clinical_epidemiology/oxford.asp Accessed 11–18.
24. Watanabe S, Tsugane S, Sobue T, Konishi M, Baba S. Study design and organization of the JPHC study. Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J Epidemiol. 2001;11:53–7.
25. Mueller M, D’Addario M, Egger M, Cevallos M, Dekkers O, Mugglin C, et al. Methods to systematically review and meta-analysis observational studies: a systematic scoping review of recommendations. BMC Med Res Methodol. 2018;18:44.

26. Yamagata H, Kiyohara Y, Nakamura S, Kubo M, Tanizaki Y, Matsumoto T, et al. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care. 2005;28:789–94.
27. Lindkvist B, Almqvist C, Bjerge T, Stocks T, Borena W, Johansen D, et al. Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic Syndrome and Cancer Project (Me-Ca). Cancer Causes Control. 2013;24:107–16.
28. Kim TJ, Lee H, Min YW, Min BH, Lee JH, Son HJ, et al. Diabetic biomarkers and the risk of proximal or distal gastric cancer. J Gastroenterol Hepatol. 2016;31:1705–10.
29. Chene G, Thompson SG. Methods for summarising the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol. 1996;144:610–21.
30. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
31. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.handbook.cochrane.org. (The Cochrane Collaboration: Available from www.handbook.cochrane.org, 2011).
32. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Identifying and quantifying heterogeneity. In: Introduction to Meta-Analysis https://doi.org/10.1002/9780470743386.ch16, 107–125 (2009).
33. Travier N, Jeffreys M, Brewer N, Wright CS, Cunningham CW, Hornell J, et al. Association between glycosylated hemoglobin and cancer risk: a New Zealand linkage study. Ann Oncol. 2007;18:1414–9.
34. Ikeda F, Doi Y, Yonemoto K, Ninomiya T, Kubo M, Shikata K, et al. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology. 2009;136:1234–41.
35. Goto A, Noda M, Sawada N, Kato M, Hidaka A, Mizoue T, et al. High hemoglobin A1c levels within the non-diabetic range are associated with the risk of all cancers. Int J Cancer. 2016;138:17–33.
36. Cheung KS, Chan EW, Wong AYS, Chen L, Seto WK, Wong ICK, et al. Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication. J Natl Cancer Inst. 2019;111:484–9.
37. Pela R, Rohan TE. Diabetes, glycated hemoglobin, and cancer risk in the uk biobank study. Cancer Epidemiol Biomark Prev. 2020;29:1107–19.
38. Lee SH, Ohr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194–202.
39. Pan XF, He M, Yu C, Lv J, Guo Y, Bian Z, et al. Type 2 diabetes and risk of incident cancer in china: a prospective study among 0.5 million chinese adults. Am J Epidemiol. 2018;187:1380–91.
40. Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2019;7:192–8.
41. Tannock IF, Kopolyan I. Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line. Cancer Res. 1986;46:3105–10.
42. Kawamura A, Adachi K, Takashima T, Fujishiro H, Yuki M, Ishihara S, et al. Helicobacter pylori-independent effect of hyperglycemia on gastric mucosal atrophy. Am J Gastroenterol. 2002;97:2479–80.
43. Su C, Wang W, Wang C. IGF-1-induced MMP-11 expression promotes the proliferation and invasion of gastric cancer cells through the JAK1/STAT3 signaling pathway. Oncol Lett. 2018;15:7000–6.
44. Guo T, Xu L, Che X, Zhang S, Li C, Wang J, et al. Formation of the IGFR1/CAV1/SRC tri-complex antagonizes TRAIL-induced apoptosis in gastric cancer cells. Cell Biol Int. 2017;41:749–60.
45. Feng XA-Q, Wang G, Lyu Z, Chen S, Wei L, Li X, et al. The association between fasting blood glucose trajectory and cancer risk in Chinese population without diabetes. Int J Cancer. 2020;147:958–66.
46. Cheung KS, Chung KL, Leung WK. Chemopreventive effect of metformin on gastric cancer development. Gut Liver. 2021; https://doi.org/10.5009/gnl210132.
47. Walker JJ, Johnson JA, Wild SH. Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. The lancet. Diabetes Endocrinol. 2013;1:132–9.
48. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist. 2010;15:548–55.
49. He C, Yang Z, Lu NH. Helicobacter pylori infection and diabetes: is it a myth or fact? World J Gastroenterol. 2014;20:6607–17.
50. Sheu SM, Cheng H, Kao CY, Yang YJ, Wu JJ, Sheu BS. Higher glucose level can enhance the H. pylori adhesion and virulence related with type IV secretion system in AGS cells. J Biomed Sci. 2014;21:96.

ACKNOWLEDGEMENTS
Susanne Gustafsson and Carl Gornitzki at Karolinska Institutet Library helped improve the search strategy.

AUTHOR CONTRIBUTIONS
Conceptualisation: Jiaojiao Zheng, Shao-Hua Xie and Jesper Lagergren. Methodology: Jiaojiao Zheng, Yunhe Gao, Shao-Hua Xie, Jesper Lagergren and Giola Santoni. Formal analysis and investigation: Jiaojiao Zheng and Yunhe Gao. Writing—original draft preparation: Jiaojiao Zheng. Writing—review and editing: Jiaojiao Zheng, Yunhe Gao, Shao-Hua Xie, Giola Santoni and Jesper Lagergren. Funding acquisition: Shao-Hua Xie and Jesper Lagergren. Resources: Giola Santoni and Jesper Lagergren. Supervision: Shao-Hua Xie, Giola Santoni and Jesper Lagergren. All authors have approved the submitted draft. Jesper Lagergren is the guarantor of the study and has the full responsibility for the conduct of the study.

FUNDING
This study was supported by the Swedish Cancer Society (180684; 190043) and the Swedish Research Council (2019-00209). JZ receives a scholarship from China Scholarship Council [201700260292]. The funding agencies were not involved in the study design, data collection and analysis, interpretation of the results, the writing of the report, or the decision to submit the article for publication. Open access funding provided by Karolinska Institute.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Not applicable.

CONSENT TO PUBLISH
Not applicable

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41416-021-01693-3.

Correspondence and requests for materials should be addressed to Shao-Hua Xie.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2021